All together, in vitro and in vivo data suggest that evaluation of FASN expression is important for selection of candidates to FASN-targeted therapy, but the tumor being positive for FASN expression is not sufficient to predict response to this therapy. The gene discussed is FASN; the disease is neoplasm.